HRS 2020: Boston Scientific’s Next-Gen LAAC Device Hits Targets In PINNACLE FLX Trial
The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.
You may also be interested in...
Results of the trial showed Amplatzer Amulet was superior to Boston Scientific’s Watchman for left-atrial appendage closure and noninferior for safety and effectiveness.
Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.